An observational study in Atrophic Scar, sponsored by CellinCells. Not yet recruiting at 1 site in South Korea. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by CellinCells · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Cicatrix with a site in Korea, Republic of — 3 open to participants now, 4 under way, none of them phase 3. Cicatrix · Korea, Republic of.
Among the 19 studies in Cicatrix with a site in Korea, Republic of, this one is one of 3 that started in 2026, is one of 3 observational ones, and was the 19th registered.
614 studies on the registry are indexed under Cicatrix; 115 are open to participants now.
Browse Cicatrix studies →3 of the 19 studies in Cicatrix with a site in Korea, Republic of are open now. Recruiting first, the newest first:
CellinCells · Sites in Korea, Republic of
Ages 19+ · Healthy volunteers
CellinCells · Sites in Korea, Republic of
Ages 19+ · Healthy volunteers
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 69 Cicatrix studies recruiting now, 34 (49%) set no upper age limit and 31 (45%) stop at 75 or younger; 11 take children under 18; 16 take healthy volunteers.
This study: 19 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 4 · Phase 3 1 · Phase 4 1
First in 2004; this study’s year is marked. 3 started in 2026.
This study's planned enrollment of 52 is below the median of 80 across 68 observational studies indexed under Cicatrix.
Median enrollment 28 across the 16 interventional studies, 31 across the 3 observational. Of the 13 that completed or were terminated, 1 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 19 have an industry lead sponsor. The 10 most frequent:
CellinCells is the lead sponsor of 5 studies on the registry; 3 are open to participants now.
CellinCells has 5 studies filed under Cicatrix — fewer than ten, so there is no comparison to draw.
1 of the studies in Cicatrix with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07945106CellinCellsDevelopment of an ASRS-Based Photoguide for a Clinical Trial of TRTP-101 in Adults With Atrophic Scars | 2027-02-26 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies in Cicatrix with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
CIC101-02-PG aims to develop an ASRS-based photoguide for patients with atrophic acne scars.
Individuals with Atrophic scars
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants classified as ASRS Grade 0
Participants classified as ASRS Grade 1
Participants classified as ASRS Grade 2
Participants classified as ASRS Grade 3
Participants classified as ASRS Grade 4
Participants are classified into five cohorts according to ASRS Grades 0-4.
Inter-rater Reliability of the Acne Scar Rating Scale (ASRS)
Inter-rater reliability of ASRS grading is assessed among three independent evaluators using standardised photographs of atrophic acne scars. Agreement among evaluators will be quantified using Fleiss' weighted kappa statistic.
Time frame: Within 4 weeks after completion of photograph collection
Intra-rater Reliability of the Acne Scar Rating Scale (ASRS)
Intra-rater reliability of ASRS grading is assessed for each of the three independent evaluators using 13 repeated photographs. Agreement between repeated assessments will be quantified using Cohen's weighted kappa statistic.
Time frame: Within 4 weeks after completion of photograph collection
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Feb 2027, 3 months later.
Of 23 observational studies under Cicatrix, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 7. This study's planned 3 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
CellinCells